
This Sheet Has Been Replaced

Abstract

The invention is concerned with compounds of the general formula



THIS SHEET HAS BEEN REPLACED

I

wherein

R^1	signifies hydrogen, lower alkyl, phenyl or benzyl,	
R^2	signifies lower alkyl, lower alkoxy, $-O(CH_2)_nN(R^{13})(R^{14})$, $-(CH_2)_nN(R^{13})(R^{14})$ or $-N(R^{15})(CH_2)_nN(R^{13})(R^{14})$,	
R^3-R^{12}	signify hydrogen, halogen, trifluoromethyl, lower alkyl, cycloalkyl, lower alkoxy, hydroxy, nitro, cyano, $-N(R^{13})_2$, phenyl, phenyloxy, benzyl or benzyloxy, or	
R^6 and R^7	together signify a benzene ring,	
R^{13}-R^{15}	signify hydrogen, lower alkyl or cycloalkyl and	
n	signifies 1-5,	

as well as their pharmaceutically acceptable salts.

These compounds are suitable for the control or prevention of acute and/or chronic neurological disorders such as restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycaemia, Alzheimer's disease, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, cognitive disorders, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, chronic pain, dyskinesia and depressions.